30 Sep 2011: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.
 
Reference is made to NorDiags stock exchange announcements on 9, 16 and 23 September 2011, in relation to the Company s financial situation, the proposed rights issue of approximately 150 million to 200 million new shares and the invitation to participate in the underwriting syndicate in the rights issue.
 
The extended underwriting invitation expired on 29 September 2011 at 17:30 CET. The company has mot received guarantee commitments for the minimum amount of NOK 15 million, but, as NorDiag has received interest from and is continuing its dialogue with potential investors, including strategic investors and parties representing other potential strategic solutions, NorDiag has decided to uphold the proposal of the rights issue in the extraordinary general meeting to be held today, 30 September 2011 at 10:00 CET.  The company will continue to work towards finding possible solutions for the company, including to obtain guarantee commitments for the rights issue. 

With regards to the potential strategic investors, there can be given no assurance that such investors will decide to invest in NorDiag at satisfactory terms, or that they will be able to make any investment decision within the short timeframe available to find a solution for NorDiag s short-term financing need. However, given the level of interest received, NorDiag s Board of Directors is of the opinion that there is a good probability to obtain a long-term strategic solution for the Company if the Company s short term financing need is solved.
 
NorDiag will make further announcements in this respect if and when appropriate.
 
 
Contact:
CEO Mårten Wigstøl            Tel: +47 911 65775
CFO Tone Kvåle                  Tel: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com

Read the notice in Norwegian here